SELLAS Life Sciences (SLS) Current Deferred Revenue (2020 - 2021)
SELLAS Life Sciences (SLS) has disclosed Current Deferred Revenue for 3 consecutive years, with $900000.0 as the latest value for Q1 2021.
- On a quarterly basis, Current Deferred Revenue changed N/A to $900000.0 in Q1 2021 year-over-year; TTM through Mar 2021 was $900000.0, a N/A change, with the full-year FY2020 number at $5.6 million, changed N/A from a year prior.
- Current Deferred Revenue was $900000.0 for Q1 2021 at SELLAS Life Sciences, down from $5.6 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $5.6 million in Q4 2020 to a low of $900000.0 in Q1 2021.